Capstone Holding Past Earnings Performance
Past criteria checks 0/6
Capstone Holding's earnings have been declining at an average annual rate of -27.3%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 54.4% per year.
Key information
-27.3%
Earnings growth rate
4.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 54.4% |
| Return on equity | -13.1% |
| Net Margin | -11.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Capstone Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 48 | -6 | 11 | 0 |
| 31 Dec 22 | 62 | 0 | 13 | 0 |
| 31 Dec 21 | 67 | 1 | 12 | 0 |
| 31 Dec 19 | 0 | 0 | 1 | 0 |
| 30 Jun 19 | 0 | -3 | 1 | 2 |
| 31 Mar 19 | 2 | -1 | 1 | 2 |
| 31 Dec 18 | 0 | -1 | 1 | 0 |
| 30 Sep 18 | 2 | -1 | 1 | 1 |
| 30 Jun 18 | 2 | 0 | 1 | 1 |
| 31 Mar 18 | 0 | -2 | 1 | 1 |
| 31 Dec 17 | 0 | -2 | 1 | 1 |
| 30 Sep 17 | 0 | -2 | 0 | 1 |
| 30 Jun 17 | 0 | 0 | 0 | 1 |
| 31 Mar 17 | 0 | -1 | 0 | 1 |
| 31 Dec 16 | 0 | -1 | 1 | 1 |
| 30 Sep 16 | 0 | -1 | 1 | 1 |
| 30 Jun 16 | 0 | -2 | 1 | 1 |
| 31 Mar 16 | 0 | -2 | 2 | 1 |
| 31 Dec 15 | 0 | -3 | 2 | 1 |
| 30 Sep 15 | 0 | -2 | 2 | 1 |
| 30 Jun 15 | 0 | -3 | 2 | 2 |
| 31 Mar 15 | 0 | -4 | 1 | 3 |
| 31 Dec 14 | 0 | -4 | 1 | 3 |
| 30 Sep 14 | 0 | -4 | 1 | 3 |
| 30 Jun 14 | 0 | -4 | 1 | 3 |
| 31 Mar 14 | 0 | -4 | 1 | 3 |
Quality Earnings: CAPS is currently unprofitable.
Growing Profit Margin: CAPS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CAPS is unprofitable, and losses have increased over the past 5 years at a rate of 27.3% per year.
Accelerating Growth: Unable to compare CAPS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CAPS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: CAPS has a negative Return on Equity (-13.11%), as it is currently unprofitable.